Table 1.
Baseline characteristics for patients with transrectal prostate biopsy at University Hospital Frankfurt between 01/2018 and 05/2019 stratified for SB and SB + TB.
| Variable | Overall | SB | SB + TB | p-value | |
|---|---|---|---|---|---|
| Patients with transrectal biopsy, n | 230 | 105 | 125 | ||
| Patients with clinical follow up, n (%) | 180 (78.3) | 84 (80) | 96 (76.8) | ||
| Age at biopsy, median (IQR) | 66 (61–72) | 66 (61–72.2) | 66 (59–71) | 0.164 | |
| PSA (ng/ml), median (IQR) | 7.8 (5.3–14.7) | 10 (6.2–46.5) | 6.9 (4.8–10.4) | 0.178 | |
| Prostate volume (ccm), median (IQR) | 45 (35–64.5) | 45 (37–70) | 40 (35–60) | 0.072 | |
| DRE suspicous for PCA, n (%) | 69 (30) | 37 (35.2) | 32 (25.6) | 0.149 | |
| Previous biopsies, n (%): | 0 | 172 (74.8) | 86 (81.9) | 86 (68.8) | 0.025 |
| 1 | 41 (17.8) | 11 (10.5) | 30 (24) | ||
| >2 | 15 (6.5) | 6 (5.7) | 9 (7.2) | ||
| Cores per biopsy, median (IQR) | 14 (12–17) | 12 (12–12) | 17 (14–20) | <0.01 | |
| Positive Cores per biopsy, median (IQR) | 3 (1–7) | 3 (1–6) | 3 (1–7) | 0.91 | |
| If PCA: ISUP Grade, n (%): | GG1 | 19 (8.3) | 10 (9.5) | 9 (7.2) | 0.032 |
| GG2 | 35 (15.2) | 10 (9.5) | 25 (20) | ||
| GG3 | 33 (14.3) | 11 (10.5) | 22 (17.6) | ||
| GG4 | 19 (8.3) | 10 (9.5) | 9 (7.2) | ||
| GG5 | 39 (17) | 25 (23.8) | 14 (11.2) | ||
| noPCA | 85 (37) | 39 (37.1) | 46 (36.8) |
SB, systemic biopsy; TB, targeted biopsy; IQR, interquartile range; PSA, prostate specific antigen; DRE, digital rectal examination; PCA, Prostate cancer; GG, Grade Group.